MARKET

RARE

RARE

Ultragenyx Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.26
+3.79
+7.36%
After Hours: 55.26 0 0.00% 16:41 05/16 EDT
OPEN
51.36
PREV CLOSE
51.47
HIGH
55.83
LOW
50.86
VOLUME
781.95K
TURNOVER
0
52 WEEK HIGH
115.25
52 WEEK LOW
49.24
MARKET CAP
3.86B
P/E (TTM)
-8.0518
1D
5D
1M
3M
1Y
5Y
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.
Benzinga · 8h ago
Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know
Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to $146.00. Shares of Ultragenyx Pharmaceutical are trading up 2.9% over the last 24 hours, at $53.30 per share.
Benzinga · 6d ago
Citigroup Adjusts Price Target on Ultragenyx Pharmaceutical to $146 From $150, Reiterates Buy Rating
MT Newswires · 6d ago
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
Oral presentations include longer term durability data from DTX301 and DTX401, and manufacturing data on the Pinnacle PCL™ (AAV vector Producer Cell Line) platform and technologyNOVATO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc...
GlobeNewswire · 05/09 12:00
Ultragenyx Pharmaceutical's price target lowered by Cowen analyst, rating maintained
Cowen analyst Yaron Werber lowered Ultragenyx Pharmaceutical's (NASDAQ:RARE) price target to $99 from $124 after Q1 results. The Outperform rating on the shares were maintained. RARE's Q1 GAAP EPS of -$2.19 misses
Seekingalpha · 05/06 16:37
Sector Update: Health Care
MT Newswires · 05/06 16:15
Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates
Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.
Zacks · 05/06 15:37
--SVB Securities Adjusts Ultragenyx Pharmaceutical's Price Target to $115 from $178, Keeps Outperform Rating
MT Newswires · 05/06 13:42
More
No Data
Learn about the latest financial forecast of RARE. Analyze the recent business situations of Ultragenyx Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

27.78%Strong Buy
50.00%Buy
22.22%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RARE stock price target is 128.81 with a high estimate of 186.00 and a low estimate of 71.00.
High186.00
Average128.81
Low71.00
Current 55.26
EPS
Actual
Estimate
-1.75-1.31-0.88-0.44
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 313
Institutional Holdings: 74.60M
% Owned: 106.68%
Shares Outstanding: 69.93M
TypeInstitutionsShares
Increased
94
3.50M
New
35
2.47M
Decreased
70
4.43M
Sold Out
19
234.47K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Non-Executive Chairman/Independent Director
Daniel Welch
President/Chief Executive Officer/Director
Emil Kakkis
Chief Financial Officer/Executive Vice President
Mardi Dier
Executive Vice President/General Counsel
Karah Parschauer
Executive Vice President
Camille Bedrosian
Executive Vice President
Erik Harris
Executive Vice President
Dennis Huang
Executive Vice President
Thomas Kassberg
Executive Vice President
John Pinion
Director
Amrit Ray
Director
Corazon Sanders
Independent Director
William Aliski
Independent Director
Deborah Dunsire
Independent Director
Lars Ekman
Independent Director
Matthew Fust
Independent Director
Michael Narachi
Independent Director
Shehnaaz Suliman
No Data
No Data
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company's therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy and nucleic acid product candidates. Its three approved product candidates include Crysvita (burosumab), for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa), for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome and Dojolvi (triheptanoin), for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD). Its clinical product candidates include DTX401, for the treatment of glycogen storage disease type Ia (GSDIa), DTX301, for the treatment of ornithine transcarbamylase (OTC), UX143, GTX-102, UX701 and UX053.

Webull offers kinds of Ultragenyx Pharmaceutical Inc stock information, including NASDAQ:RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.